Video Experimental Relacionado
Updated: Sep 10, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Uso de tecnología avanzada para el tratamiento de la diabetes tipo 1 en el embarazo
Ina Geerts1, Katrien Benhalima2
1Clinical and Experimental Endocrinology, KU Leuven, Belgium.
Best practice & research. Clinical endocrinology & metabolism
|August 24, 2025
Resumen
Los sistemas automatizados de administración de insulina (AID) mejoran el control glucémico en mujeres embarazadas con diabetes tipo 1. Los estudios muestran un aumento del tiempo en el rango y el uso seguro durante el parto y el posparto, pero los resultados maternos / neonatales requieren más investigación.
Área de la Ciencia:
- Endocrinología
- Medicina de la reproducción
- Tecnología médica
Sus antecedentes:
- Los sistemas automatizados de administración de insulina (AID) han transformado el manejo de la diabetes tipo 1.
- El uso creciente de AID preconcepción requiere entender su papel durante el embarazo.
- Existen datos limitados sobre la eficacia y seguridad de los AID en mujeres embarazadas.
Objetivo del estudio:
- Revisar la evidencia actual sobre la eficacia y la seguridad de los sistemas AID en el embarazo y el posparto.
- Evaluar el impacto de AID en el control glucémico en mujeres embarazadas con diabetes tipo 1.
- Explorar los beneficios potenciales de la AID en los resultados maternos y neonatales.
Principales métodos:
- Revisión de ensayos controlados aleatorios (ECA) y datos recientes sobre el uso de AID en el embarazo.
- Análisis de estudios en los que se han utilizado sistemas específicos de detección auxiliar como CamAPS® FX y MiniMedTM 780G.
- Examen de los datos de seguridad durante el trabajo de parto y el período posparto.
Principales resultados:
- Un gran ECA demostró un aumento del 10% en el tiempo en el rango con CamAPS® FX en comparación con el tratamiento estándar.
- El CamAPS® FX es el único sistema AID aprobado para su uso durante el embarazo.
- El sistema MiniMedTM 780G también mostró beneficios sobre la terapia de insulina estándar.
- AID parece seguro para la continuación durante el trabajo de parto y postparto.
Conclusiones:
- Los sistemas AID son prometedores para mejorar el control glucémico en mujeres embarazadas con diabetes tipo 1.
- La evidencia actual apoya la seguridad de continuar con AID durante el parto y el posparto.
- Se necesita más investigación para determinar si la AID mejora los resultados maternos y neonatales.
Más Videos Relacionados
08:16Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
Published on: March 15, 2024
1.6K
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
8.0K
Videos de Conceptos Relacionados
01:22Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
01:15Diabetes: Management and Pharmacotherapy
362
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
362
01:22Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
01:20Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
01:16Insulin: Dosing Regimen and Adverse Effects
257
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
257
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416